TYRA

Tyra Biosciences, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001863127
$25.94 -3.03% $1.6B
4 Institutional Exits
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders7 funds
Inst. Value$54.6M
Inst. Activity1 buys / 4 sells
Insider Activity0B / 2S
Insider Net $-$595.5K
SEC Reports5
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001863127·Prev Close $26.75

Recent Activity

Jun 9, 2026 short_volume
Short Volume: TYRA — 59.1% short (0.4M / 0.6M)
Short: 352,701 | Exempt: 0 | TRF Vol: 597,064 | Short Ratio: 59.1% | Off-exchange volume (dark pool
May 28, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. sold 13,160 shares
Director @ $0.00 ($0.00)
May 28, 2026 Insider
Verjee Rehan sold 13,160 shares
Director @ $0.00 ($0.00)
May 28, 2026 Insider
Moran Susan sold 13,160 shares
Director @ $0.00 ($0.00)
May 13, 2026 SEC
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R
8-K — Impact 5/10
Apr 20, 2026 SEC
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorney to the company's
3 — Impact 2/10
Apr 17, 2026 SEC
Tyra Biosciences is holding its annual shareholder meeting to elect three directors, including Habib J. Dable, whose rec
DEFA14A — Impact 4/10
Inst.
MORGAN STANLEY — TRIM
118,898 shares ($3.1M)

Price Targets

$51.15 +97.2% upside Strong Buy
Current $25.94 Low $37.00 Median $53.00 High $59.62 11 analysts
$37.00 $59.62

Analyst Ratings

Strong Buy90% buy · 21 analysts
9Strong Buy
10Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 19, 2026 Wolfe Research INITIATE Peer Perform
May 14, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Apr 15, 2026 Guggenheim INITIATE Buy
Apr 6, 2026 Canaccord Genuity INITIATE Buy
Mar 20, 2026 Piper Sandler MAINTAIN Overweight → Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.64 ▼ -11.2% $-0.70 — $-0.56 -36% YoY 13
Next Q $-0.65 ▼ -9.0% $-0.76 — $-0.53 -29% YoY 13
Current FY $-2.57 ▼ -10.7% $-2.87 — $-2.31 -28% YoY 13
Next FY $-2.84 ▼ -10.6% $-3.52 — $-2.26 -11% YoY 13

Latest Reports

MIXED 8-K 5/10
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago, reflecting higher R
May 13, 2026
NEUTRAL 3 2/10
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorney to the company's
Apr 20, 2026

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$41.3M—
CHARLES SCHWAB INVESTMENT MANAGEMENT$5.2MNEW
MORGAN STANLEY$3.1MTRIM
TWO SIGMA INVESTMENTS, LP$2.8MTRIM
BANK OF AMERICA CORP$1.0MTRIM

Recent Insider Trades

DateInsiderTypeValue
May 28, 2026RA CAPITALA$0.00
May 28, 2026Verjee RehanA$0.00
May 28, 2026Moran SusanA$0.00
May 28, 2026Rothenberg StephenA$0.00
May 28, 2026MORE ROBERTA$0.00
7 institutional holders with $54.6M total value (2,078,054 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net selling activity: 4 institutions trimmed/exited vs 1 added.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC1,572,785$41.3M75.7%—
2CHARLES SCHWAB INVESTMENT MANAGEMENT INC199,426$5.2M9.6%NEW
3MORGAN STANLEY118,898$3.1M5.7%TRIM -63.1%
4TWO SIGMA INVESTMENTS, LP107,023$2.8M5.2%TRIM -46.3%
5BANK OF AMERICA CORP /DE/38,310$1.0M1.8%TRIM -71.5%
6WELLS FARGO & COMPANY/MN29,049$763.7K1.4%ADD +57.3%
7FMR LLC12,563$330.3K0.6%NEAR_EXIT -99.3%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
MORGAN STANLEYTRIM322,143118,898-63.1%$3.1M2025-Q4
TWO SIGMA INVESTMENTS, LPTRIM199,438107,023-46.3%$2.8M2025-Q4
BANK OF AMERICA CORP /DE/TRIM134,31938,310-71.5%$1.0M2025-Q4
WELLS FARGO & COMPANY/MNADD18,47029,049+57.3%$763.7K2025-Q4
RENAISSANCE TECHNOLOGIES LLCEXIT170,1000-100.0%$0.002025-Q4
TWO SIGMA INVESTMENTS, LPADD105,825199,438+88.5%$2.8M2025-Q3
RENAISSANCE TECHNOLOGIES LLCADD135,100170,100+25.9%$2.4M2025-Q3
BANK OF AMERICA CORP /DE/TRIM372,967134,319-64.0%$1.9M2025-Q3
UBS Group AGADD46,26859,144+27.8%$827.4K2025-Q3
MORGAN STANLEYDOUBLED180,590378,402+109.5%$3.6M2025-Q2
BANK OF AMERICA CORP /DE/DOUBLED83,521372,967+346.6%$3.6M2025-Q2
RENAISSANCE TECHNOLOGIES LLCDOUBLED51,400135,100+162.8%$1.3M2025-Q2
TWO SIGMA INVESTMENTS, LPADD64,818105,825+63.3%$1.0M2025-Q2
WELLS FARGO & COMPANY/MNADD9,35315,457+65.3%$147.9K2025-Q2
FMR LLCNEAR_EXIT1,707,14812,202-99.3%$116.8K2025-Q2
FMR LLCTRIM3,107,9701,707,148-45.1%$15.9M2025-Q1
MORGAN STANLEYDOUBLED74,149180,590+143.6%$1.7M2025-Q1
CITADEL ADVISORS LLCADD65,387115,882+77.2%$1.1M2025-Q1
TWO SIGMA INVESTMENTS, LPADD46,26964,818+40.1%$602.8K2025-Q1
RENAISSANCE TECHNOLOGIES LLCADD29,10051,400+76.6%$478.0K2025-Q1
CITADEL ADVISORS LLCADD46,65265,387+40.2%$908.9K2024-Q4
UBS Group AGDOUBLED10,96447,851+336.4%$665.1K2024-Q4
RENAISSANCE TECHNOLOGIES LLCNEW—29,100—$404.5K2024-Q4
WELLS FARGO & COMPANY/MNADD6,2579,493+51.7%$132.0K2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW—173,737—$4.1M2024-Q3
14 unique insiders with 2 transactions. Net insider value: -$595.5K ($0.00 bought, $595.5K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 28, 2026RA CAPITAL MANAGEMENT, L.P.DirectorA13,160$0.00$0.00
May 28, 2026Verjee RehanDirectorA13,160$0.00$0.00
May 28, 2026Moran SusanDirectorA13,160$0.00$0.00
May 28, 2026Rothenberg Stephen MichaelDirectorA13,160$0.00$0.00
May 28, 2026MORE ROBERT JDirectorA13,160$0.00$0.00
May 28, 2026Gulfo Adele M.DirectorA13,160$0.00$0.00
May 5, 2026Rueb YuliyaVice President, Finance (PAO)A28,000$0.00$0.00
May 5, 2026Rueb YuliyaVice President, Finance (PAO)A8,333$0.00$0.00
May 5, 2026Ashar BhaveshChief Operating OfficerA50,295$0.00$0.00
May 5, 2026Ashar BhaveshChief Operating OfficerA15,013$0.00$0.00
May 5, 2026Harris ToddPresident and CEOA265,000$0.00$0.00
May 5, 2026Harris ToddPresident and CEOA79,000$0.00$0.00
May 5, 2026Fuhrman AlanChief Financial OfficerA67,000$0.00$0.00
May 5, 2026Fuhrman AlanChief Financial OfficerA20,000$0.00$0.00
May 5, 2026Warner Douglas JChief Medical OfficerA85,000$0.00$0.00
May 5, 2026Warner Douglas JChief Medical OfficerA25,000$0.00$0.00
Apr 16, 2026Dable Habib JDirectorA44,400$0.00$0.00
Mar 26, 2026KAPLAN GILLADirectorD53,172$37.75$2.0M
Mar 26, 2026KAPLAN GILLADirectorM53,172$0.00$0.00
Mar 26, 2026KAPLAN GILLADirectorM53,172$2.25$119.6K
Mar 25, 2026KAPLAN GILLADirectorM14,295$0.00$0.00
Mar 25, 2026KAPLAN GILLADirectorM14,295$2.25$32.2K
Mar 25, 2026KAPLAN GILLADirectorSELL14,295$36.97$528.5K
Mar 13, 2026Harris ToddPresident and CEOA1,463$9.13$13.4K
Mar 13, 2026Fuhrman AlanChief Financial OfficerA1,376$9.13$12.6K
Feb 12, 2026Bensen DanielChief Discovery OfficerSELL2,128$31.50$67.0K
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 4 neutral. Avg impact: 3.2/10.
MIXED 8-K 5/10
Tyra Biosciences reported Q1 2026 net loss of $39.3M ($0.64 per share) vs $28.1M ($0.47) a year ago,
May 13, 2026
NEUTRAL 3 2/10
Habib J. Dable, a reporting person at Tyra Biosciences, filed a Form 3 and granted a power of attorn
Apr 20, 2026
NEUTRAL DEFA14A 4/10
Tyra Biosciences is holding its annual shareholder meeting to elect three directors, including Habib
Apr 17, 2026
NEUTRAL 8-K 3/10
Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effectiv
Apr 17, 2026
NEUTRAL 144 2/10
Daniel Bensen, an officer of Tyra Biosciences, filed a Form 144 to notify intent to sell up to 8,000
Apr 13, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (90% buy). Based on 21 analysts: 9 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$51.15 mean target +97.2% upside Strong Buy (1.29)
$37.00 Low $59.62 High
MetricValue
Current Price$25.94
Target Low$37.00
Target Mean$51.15
Target Median$53.00
Target High$59.62
# Analysts11
RecommendationStrong Buy (1.29)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.64 $-0.70 $-0.56 -35.9% -11.2% 1↑ 8↓ $0.0B 0.0% 13
Next Q
2026-09-30
 $-0.65 $-0.76 $-0.53 -29.4% -9.0% 2↑ 7↓ $0.0B 0.0% 13
Current FY
2026-12-31
 $-2.57 $-2.87 $-2.31 -27.6% -10.7% 1↑ 7↓ $0.0B 0.0% 13
Next FY
2027-12-31
 $-2.84 $-3.52 $-2.26 -10.6% -10.6% 1↑ 8↓ $0.0B 0.0% 13

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.639
7d ago$-0.639
30d ago$-0.574-0.064
60d ago$-0.573-0.066
90d ago$-0.562-0.077
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 19, 2026 Wolfe Research INITIATE — Peer Perform
May 14, 2026 HC Wainwright & Co. REITERATE Buy Buy
Apr 15, 2026 Guggenheim INITIATE — Buy
Apr 6, 2026 Canaccord Genuity INITIATE — Buy
Mar 20, 2026 Piper Sandler MAINTAIN Overweight Overweight
Feb 24, 2026 Cantor Fitzgerald INITIATE — Overweight
Feb 17, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 13, 2026 Wedbush MAINTAIN Outperform Outperform
Feb 3, 2026 Oppenheimer MAINTAIN Outperform Outperform
Feb 3, 2026 Jefferies MAINTAIN Buy Buy
Jan 28, 2026 Barclays INITIATE — Overweight
Jan 23, 2026 Piper Sandler MAINTAIN Overweight Overweight
Dec 16, 2025 Wedbush MAINTAIN Outperform Outperform

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202691020090%
May 1, 202691010095%
Apr 1, 20268910094%
Mar 1, 20268910094%
Feb 1, 20267810094%
Jan 1, 20267710093%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 9, 2026
short_volume
Short Volume: TYRA — 59.1% short (0.4M / 0.6M)
Short: 352,701 | Exempt: 0 | TRF Vol: 597,064 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: TYRA — 57.2% short (0.4M / 0.6M)
Short: 350,487 | Exempt: 0 | TRF Vol: 612,900 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TYRA — 59.4% short (0.4M / 0.7M)
Short: 423,912 | Exempt: 310 | TRF Vol: 714,104 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: TYRA — 62.8% short (0.4M / 0.6M)
Short: 377,462 | Exempt: 0 | TRF Vol: 600,870 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
TYRA Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
earnings_calendar
TYRA Q1 2026 Earnings Scheduled — 2026-04-30
Apr 24, 2026
short_volume
Short Volume: TYRA — 57.3% short (0.3M / 0.6M)
Short: 315,524 | Exempt: 0 | TRF Vol: 550,230 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: TYRA — 60.6% short (0.3M / 0.6M)
Short: 345,654 | Exempt: 2,614 | TRF Vol: 569,930 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_interest
FTD: TYRA — 61,808 shares ($2.4M) failed to deliver
Settlement: 20260402, Price: $38.28, FTD Value: $2,366,010.24, TYRA BIOSCIENCES INC COM (DE)
Mar 30, 2026
short_volume
Short Volume: TYRA — 77.3% short (0.7M / 0.8M)
Short: 655,867 | Exempt: 282 | TRF Vol: 848,392 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_interest
FTD: TYRA — 14,376 shares ($0.5M) failed to deliver
Settlement: 20260323, Price: $37.15, FTD Value: $534,068.4, TYRA BIOSCIENCES INC COM (DE)
Mar 11, 2026
short_interest
FTD: TYRA — 128,036 shares ($4.4M) failed to deliver
Settlement: 20260311, Price: $34.74, FTD Value: $4,447,970.64, TYRA BIOSCIENCES INC COM (DE)
Mar 5, 2026
short_interest
FTD: TYRA — 484,466 shares ($17.1M) failed to deliver
Settlement: 20260305, Price: $35.27, FTD Value: $17,087,115.82, TYRA BIOSCIENCES INC COM (DE)
Feb 9, 2026
short_interest
FTD: TYRA — 63,625 shares ($2.0M) failed to deliver
Settlement: 20260209, Price: $31.00, FTD Value: $1,972,375, TYRA BIOSCIENCES INC COM (DE)